News

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

A resurgence in this IOL technology could create new possibilities in refractive correction

The study assessed a large paediatric cohort for changes in spherical equivalent refraction, axial length, lens power and lens thickness

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Epi-on corneal crosslinking is advancing through innovations like supplemental oxygen, chemical oxygenation, and laser-assisted techniques.

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal endothelial disease.

Vision correction has evolved into a continuum of procedures suited for different stages of ocular maturity

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects of one intravitreal dexamethasone implant in eyes with refractory diabetic macular edema.

Brazilian researchers conducted a study comparing two treatments for postoperative endophthalmitis. They found that pars plana vitrectomy followed by an intravitreal antibiotic injection (PPV + IVAIES) was more effective than using an intravitreal antibiotic injection alone (IVAI).

One intravitreal injection of the dexamethasone implant in patients with refractory DME induced significant anatomic and functional improvements, but these improvements only lasted for short periods of up to 4 months.

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.

To create lasting change, ophthalmology must embrace the impact of sponsorship and advocacy—empowering the next generation of leaders with not just knowledge, but the opportunities to excel.

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3.

A combination of canaloplasty and goniotomy provides sustained IOP reduction and decreases medication burden with a strong safety profile, making it a valuable option for glaucoma management.

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3

An AI model for target IOP prediction performs as well as glaucoma specialists, offering a promising tool to enhance glaucoma management, especially for nonspecialists.

The acquisition also includes the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology and LENSAR legacy laser system.

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration